Pharma BD Deal Intelligence
A consolidation deal: BioNTech's all-stock buyout of CureVac at ~$5.46 per share (~$1.25B implied equity) ended years of patent litigation and closed December 18, 2025, with BioNTech taking CureVac to 100% ownership by January 2026 -- though the payoff rests on folding CureVac's oncology pipeline into BioNTech's own.
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →BioNTech will acquire CureVac in an all-stock deal worth approximately $1.25 billion, consolidating two of the world's leading mRNA companies and ending a…
BioNTech said on Thursday it would buy smaller rival CureVac in an all-stock deal valued at about $1.25 billion, as the German vaccine maker bets on…
BioNTech closed the CureVac acquisition on December 18, 2025; ~86.75% (195,341,219) of CureVac shares were validly tendered, and BioNTech expects to complete…
Source summaries from our enrichment pipeline; follow links for originals.
All 12 sources with sentiment breakdown →
BioNTech announced all-stock acquisition of CureVac in public exchange offer, ~$5.46 per CureVac share in BioNTech ADSs, total implied equity value ~$1.25B. Strengthens BioNTech's mRNA oncology platform and resolves prior patent litigation. Closed December 18, 2025. BioNTech completed the post-offer compulsory acquisition of the residual minority shares in January 2026, taking CureVac to 100% ownership and ending its public listing.
2.0M US cases/yr · $3.0B Projected mRNA cancer immunotherapy peak sales range (analyst consensus, multi-indication) · ~50% 5-year recurrence rate in high-risk resected stage III melanoma despite adjuvant anti-PD-1 - the lead mRNA INT indication
The mRNA cancer immunotherapy field targets solid tumors through two primary approaches: personalized cancer vaccines (individualized neoantigen therapies, INTs) that encode patient-specific tumor mutations, and off-the-shelf mRNA vaccines encoding shared tumor-associated antigens. Lead clinical indications for late-stage mRNA oncology programs include adjuvant melanoma (high recurrence risk post-resection), non-small-cell lung cancer (NSCLC), pancreatic ductal adenocarcinoma (PDAC), head and neck squamous cell carcinoma (HNSCC), and muscle-invasive bladder cancer. The American Cancer Society projects approximately 2.04 million new US cancer cases and 618,000 cancer deaths in 2025. Resected melanoma alone affects ~104,960 new US cases annually with roughly 8,000 deaths, and high-risk stage III melanoma has a 5-year recurrence rate approaching 50% despite adjuvant anti-PD-1 therapy, defining the marquee unmet need being addressed by Moderna/Merck's mRNA-4157 (INT). BioNTech's acquisition of CureVac consolidates the two largest European mRNA platforms, resolves ongoing patent litigation between the companies, and combines BioNTech's iNeST (BNT122/autogene cevumeran) and FixVac (BNT111, BNT113) programs with CureVac's mRNA manufacturing and format IP.
The mRNA cancer immunotherapy competitive set is led by Moderna/Merck's mRNA-4157 (intismeran autogene) paired with Keytruda - Phase 3 INTerpath-001 in adjuvant melanoma and INTerpath-002 in adjuvant NSCLC are Breakthrough-designated and expected to read out 2026-2027. BioNTech's own programs include BNT122/autogene cevumeran (Phase 2 adjuvant PDAC + CRC, partnered with Genentech/Roche) and BNT111 (FixVac melanoma, Phase 2). CureVac pre-acquisition was running mRNA-based cancer vaccine programs including CVGBM (glioblastoma) and CVHNLC (squamous NSCLC). Non-mRNA personalized cancer vaccine competitors include Geneos Therapeutics (DNA-based GNOS-PV02, HCC), Gritstone bio (self-amplifying RNA GRANITE + SLATE, MSS CRC), Transgene/NEC (TG4050 viral-vectored, HNSCC), and Nouscom (CoVac adenoviral, MSS CRC). Post-acquisition, BioNTech consolidates the largest European mRNA oncology pipeline with multi-format capability (lipoplex, protamine-complexed, LNP), manufacturing scale in Mainz/Marburg/Tubingen, and resolves CureVac's patent litigation overhang.
Following the December 18, 2025 close (~86.75% tendered), BioNTech completed the previously announced post-offer compulsory acquisition / squeeze-out of the remaining CureVac shares in early January 2026, taking ownership to 100%; CureVac shares ceased trading. Exchange ratio 0.05363 BioNTech ADS per CureVac share (~$5.46/share, 55% premium); total implied equity value ~$1.25B.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| BioNTech SE / CureVac N.V. (this deal) | 2025 | $1.2B | — |
| BioNTech SE / Duality Biologics (Suzhou) Co. Ltd. | 2023 | $1.7B | — |
| BioNTech SE / Biotheus Inc. (Pumai Biotechnology) | 2024 | $950M | — |
| BioNTech SE / Kite Pharma (Gilead Sciences) | 2021 | $250M | — |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
| Novartis AG / Endocyte, Inc. | 2018 | $2.1B | 96 |
| Astellas Pharma Inc. / Seagen Inc. | 2009 | $4.5B | 95 |
← Browse all deals · How we score deals
More: 2025 deals · BioNTech SE deals · Oncology deals